Skip to main content
4SC AG logo

4SC AG — Investor Relations & Filings

Ticker · VSC ISIN · DE000A3E5C40 LEI · 391200QOKN7LGVP0RQ86 F Manufacturing
Open in API
Filings indexed 719 across all filing types
Latest filing 2011-06-14 Declaration of Voting R…
Country DE Germany
Listing F VSC

About 4SC AG

https://www.4sc.com/

4SC AG is a biopharmaceutical company that formerly focused on the research and development of small-molecule drugs for cancer treatment. The company's strategy centered on addressing diseases with high unmet medical needs by developing innovative therapies that targeted epigenetic mechanisms of action. According to the company's official statements, it currently has no products under development and no operational business.

Recent filings

Filing Released Lang Actions
Release according to Article 26a of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document explicitly states it is a 'Total Voting Rights Announcement' according to Article 26a of the WpHG. It reports the total number of voting rights (41,968,304) as of the end of May 2011. This type of announcement, which details the total number of shares carrying voting rights, is a specific regulatory disclosure. Among the provided definitions, 'Declaration of Voting Results & Voting Rights Announcements' (DVA) is the most appropriate fit, as it covers announcements related to voting rights, even if it's not the result of a specific vote, but rather the total outstanding voting power.
2011-06-14 English
4SC Announces Topline Results of Phase IIb Trial of Vidofludimus in Rheumatoid Arthritis
Regulatory Filings Classification · 99% confidence The document is a press release dated June 8, 2011, announcing the 'Topline Results of Phase IIb Trial of Vidofludimus in Rheumatoid Arthritis'. It details clinical trial efficacy data (ACR20, ACR50, ACR70 responses), safety findings, and management commentary on the results and future partnering discussions. It also announces a conference call to discuss these results. This content structure—announcing key results from a specific period/trial, often followed by a call announcement—is characteristic of an Earnings Release (ER) or a general announcement of significant operational/research news. Since it is focused purely on research trial results rather than comprehensive financial performance for a fiscal period (like a 10-K or IR), and it is an initial announcement of these results, 'Earnings Release' (ER) is the closest fit among the provided options for a significant, time-sensitive operational update that drives investor interest, even though it's R&D focused rather than purely financial earnings. It is not a full report (10-K, IR), a presentation (IP), or a transcript (CT). It is an announcement of results.
2011-06-08 English
4SC Announces Topline Results of Phase IIb Trial of Vidofludimus in Rheumatoid Arthritis
Regulatory Filings Classification · 99% confidence The document is explicitly labeled as an "Ad-hoc" announcement disseminated according to § 15 WpHG (German Securities Trading Act), which mandates immediate disclosure of price-sensitive information. The content details the topline results of a Phase IIb clinical trial for a drug (Vidofludimus) in Rheumatoid Arthritis, including statistical significance of endpoints (ACR20, ACR50, ACR70) and safety data. This type of announcement, disclosing material, non-public information about clinical trial progress, is a form of regulatory disclosure. Since it is not a full Annual Report (10-K), a comprehensive Interim Report (IR), an Earnings Release (ER), or a specific management/board change, it falls best under the general category for regulatory announcements that don't fit elsewhere, which is Regulatory Filings (RNS). It is not an announcement *about* a report (RPA), but the report/disclosure itself.
2011-06-08 English
4SC to Present at the Jefferies 2011 Global Healthcare Conference
Regulatory Filings Classification · 100% confidence The document is a short corporate news release dated May 30, 2011, announcing that the CFO of 4SC AG will present at the Jefferies 2011 Global Healthcare Conference in June. It contains no financial statements, audit opinions, management discussions, or detailed regulatory disclosures like a 10-K or IR. It is a general announcement regarding corporate activity (investor relations/conference attendance). Since it doesn't fit specific categories like ER, DIV, or MANG, and is a general corporate update distributed via a news service (DGAP), it falls best under the general 'Regulatory Filings' or 'Report Publication Announcement' category. Given the content is purely informational about an upcoming event rather than the publication of a formal report, 'Regulatory Filings' (RNS) serves as the most appropriate general category for miscellaneous corporate news releases that don't fit elsewhere.
2011-05-30 English
EULAR 2011 - Vidofludimus Superior to Cyclophosphamide and MMF in an Experimental Systemic Lupus Erythematosus Model
Regulatory Filings Classification · 90% confidence The document is a press release dated May 27, 2011, from 4SC AG announcing the presentation of preclinical data on their drug candidate vidofludimus at the EULAR 2011 conference. It details research findings related to autoimmune diseases (SLE) and compares the drug's efficacy to existing treatments. This content is a research update or scientific announcement, not a formal regulatory filing like a 10-K, an earnings release (ER), or a comprehensive interim report (IR). Since there is no specific category for 'Research Update' or 'Scientific Presentation Announcement', and it is a news release detailing corporate activity and research progress, the most appropriate general category is 'Regulatory Filings' (RNS) as a catch-all for corporate news that doesn't fit the highly specific financial/governance categories, or potentially 'LTR' if it were about legal proceedings, which it is not. Given the context of presenting research findings, RNS is the best fit among the provided options for a general corporate news announcement that isn't financial results or governance.
2011-05-27 English
4 SC AG: Bekanntmachung der Einberufung zur Hauptversammlung am 04.07.2011 in Munchen mit dem Ziel der europaweiten Verbreitung gema 121 AktG
AGM Information Classification · 99% confidence The document is an official invitation ('Einladung') to the Annual General Meeting ('ordentlichen Hauptversammlung 2011') of 4SC AG, scheduled for July 4, 2011. The text details the agenda items (Tagesordnung), which include the presentation of the 2010 annual financial statements, discharge of management/supervisory boards, auditor appointment for 2011, and crucially, a resolution regarding the amendment of the articles of association concerning authorized capital ('Genehmigtes Kapital'). Since the core purpose of this document is to convene the shareholders for the AGM and outline the voting matters, it directly falls under the category of AGM Information.
2011-05-25 German

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.